Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px
Document › Details

Novacyt S.A.. (10/18/17). "Press Release: Proposed Admission to Trading on AIM and Successful Capital Riase of €9.7 Million [Not for US, AU, CA, JP or ZA or any other jurisdiction where unlawful]". Paris & Cambridge.

Region Region London, Greater London
  Country United Kingdom (GB)
Organisations Organisation Novacyt S.A. (Alternext: ALNOV)
  Group Novacyt (Group)
  Organisation 2 Stifel Nicolaus Europe Ltd.
  Group Stifel (Group)
Products Product investment banking
  Product 2 LIFE SCIENCES
Index term Index term Novacyt–SEVERAL: investment, 201710 capital increase €9.7m with 14.74m new shares at €0.66/share
Persons Person Mullis, Graham (Novacyt 201409 CEO before Lab21 CEO)
  Person 2 Dyer, Anthony (Novacyt 201409– Finance Director before part time Group Financial Controller)
     


   
Record changed: 2017-10-30

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px

More documents for Novacyt (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top